EFFICACY AND SAFETY OF OPEN-LABEL CAPLACIZUMAB IN PATIENTS WITH EXACERBATIONS OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING THE PHASE III HERCULES STUDY

被引：0
|
作者：
Peyvandi, F.
Scully, M.
Cataland, S.
Coppo, P.
Knoebl, P.
Kremer Hovinga, J.
Metjian, A.
de la Rubia, J.
Pavenski, K.
Callewaert, F.
Biswas, D.
De Winter, H.
Zeldin, R. K.
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England
[4] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA
[5] St Antoine Univ Hosp, Dept Hematol, Paris, France
[6] Vienna Univ Hosp, Div Hematol & Hemostasis, Dept Med 1, Vienna, Austria
[7] Bern Univ Hosp, Univ Clin Hematol, Inselspital, Bern, Switzerland
[8] Bern Univ Hosp, Cent Hematol Lab, Inselspital, Bern, Switzerland
[9] Duke Univ, Sch Med, Div Hematol, Durham, NC USA
[10] Univ Catolica Valencia Hosp Doctor Peset, Hematol Dept, Valencia, Spain
[11] St Michaels Hosp, Dept Lab Med & Pathobiol, Res Inst, Toronto, ON, Canada
[12] Ablynx NV, Clin Dev, Zwijnaarde, Belgium
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO031
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [41] SAFETY PROFILE OF CAPLACIZUMAB DURING THE PHASE III HERCULES STUDY: FREQUENCY OF ADVERSE EVENTS ACCORDING TO STUDY PERIOD
    Peyvandi, F.
    Scully, M.
    Cataland, S.
    Coppo, P.
    Knoebl, P.
    Hovinga, J. Kremer
    Metjian, A.
    de la Rubia, J.
    Pavenski, K.
    Callewaert, F.
    Biswas, D.
    De Winter, H.
    Zeldin, R. K.
    HAEMATOLOGICA, 2018, 103 : S88 - S88
  • [42] A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A
    Shima, Midori
    Amano, Kagehiro
    Ogawa, Yoshiyuki
    Yoneyama, Koichiro
    Ozaki, Ryoto
    Kobayashi, Ryota
    Sakaida, Emiko
    Saito, Makoto
    Okamura, Takashi
    Ito, Toshihiro
    Hattori, Norimichi
    Higasa, Satoshi
    Suzuki, Nobuaki
    Seki, Yoshinobu
    Nogami, Keiji
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (03) : 534 - 545
  • [43] Efficacy and safety of caplacizumab without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura - a phase 3 study
    Gunawardena, S.
    Hu, A.
    Menapace, L. A.
    Okada, H.
    Accomanda, B.
    Lin, J.
    Knoebl, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 92 - 92
  • [44] Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
    Peng, Jia-Ying
    Wang, Si-Yang
    Chen, Miao-Qi
    Liu, Cheng-Xin
    Zhao, Yi-Ting
    Xu, Tong-Shan
    Wu, Qian-Long
    BLOOD COAGULATION & FIBRINOLYSIS, 2024, 35 (05) : 271 - 278
  • [45] An Open-Label, Phase III Study to Assess the Efficacy and Safety of Cysteamine Ophthalmic Solution 0.55% in Japanese Cystinosis Patients
    Goi, Nobuhiro
    Iwata, Fumino
    Sugihara, Yoko
    Higa, Shingo
    Chikama, Taiichiro
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 3457 - 3471
  • [46] EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES: AN OPEN-LABEL, PHASE-III, EXTENSION STUDY
    Brogan, P. A.
    Hofer, M.
    Kuemmerle-Deschner, J. B.
    Lauwerys, B.
    Speziale, A.
    Leon, K.
    Wei, X.
    Laxer, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 620 - 621
  • [47] Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III
    Suhler, Eric B.
    Adan, Alfredo
    Brezin, Antoine P.
    Fortin, Eric
    Goto, Hiroshi
    Jaffe, Glenn J.
    Kaburaki, Toshikatsu
    Kramer, Michal
    Lim, Lyndell L.
    Muccioli, Cristina
    Quan Dong Nguyen
    Van Calster, Joachim
    Cimino, Luca
    Kron, Martina
    Song, Alexandra P.
    Liu, Jianzhong
    Pathai, Sophia
    Camez, Anne
    Schlaen, Ariel
    van Velthoven, Mirjam E. J.
    Vitale, Albert T.
    Zierhut, Manfred
    Tari, Samir
    Dick, Andrew D.
    OPHTHALMOLOGY, 2018, 125 (07) : 1075 - 1087
  • [48] A Phase 3 Study to Evaluate the Efficacy and Safety of Caplacizumab without First-Line Therapeutic Plasma Exchange in Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Gunawardena, Sriya
    Hu, Angela
    Menapace, Laurel A.
    Okada, Hikaru
    Accomando, Beverly
    Lin, Julie
    BLOOD, 2022, 140 : 2770 - 2771
  • [49] Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study
    Jang, Jun Ho
    Tomiyama, Yoshiaki
    Miyazaki, Koji
    Nagafuji, Koji
    Usuki, Kensuke
    Uoshima, Nobuhiko
    Fujisaki, Tomoaki
    Kosugi, Hiroshi
    Matsumura, Itaru
    Sasaki, Ko
    Kizaki, Masahiro
    Sawa, Masashi
    Hidaka, Michihiro
    Kobayashi, Naoki
    Ichikawa, Satoshi
    Yonemura, Yuji
    Enokitani, Kouki
    Matsuda, Akira
    Ozawa, Keiya
    Mitani, Kinuko
    Lee, Jong Wook
    Nakao, Shinji
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (01) : 190 - 199
  • [50] EVALUATING THE LONG-TERM EFFICACY OF ROMIPLOSTIM (AMG 531) IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) DURING AN OPEN-LABEL EXTENSION STUDY
    Newland, C.
    Sanz, M. A.
    Bourgeois, E.
    Grande, C.
    Boekhorst, P. A. W. te
    Vellenga, E.
    Shi, Y.
    Berger, D.
    Kuter, D. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 377 - 377
12345